MeSH D014516 - ureteral neoplasms
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Merck Sharp & Dohme | Pembrolizumab | Keytruda | 2014-09-04 | $26,163 M | Q2/23-Q1/24 |
Clinical Trials
Historical Success Rate
Phase 1
67%12/18
Phase 2
27%11/41
Phase 3
10%2/20
Approved: 1Overall Success rate: 2%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use